Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Erectile Dysfunction II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male, at least 19 years of age~* Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity~* History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration~* Partner is not pregnant or lactating~Exclusion Criteria:~* History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months~* Cardiac arrhythmias requiring antiarrhythmic treatment~* Symptomatic congestive heart failure~* Taking nitrate medication in any form~* Uncontrolled diabetes (HbA1c ≥ 13%)~* Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®~* Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Udenafil 50 mg (Type: EXPERIMENTAL): 50 mg Udenafil tablet plus 100 \& 150 mg placebo tablets
- Udenafil 100 mg (Type: EXPERIMENTAL): 100 mg Udenafil tablet plus 50 \& 150 mg placebo tablets
- Udenafil 150mg (Type: EXPERIMENTAL): 150 mg Udenafil tablet plus 50 \& 100 mg placebo tablets
- Placebo (Type: PLACEBO_COMPARATOR): 50, 100 \& 150 mg placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).